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Abstract
Background: Agonist antibodies against CD137 (4–1BB) on T lymphocytes are used to increase host anti-tumor immunity,
but often leading to severe liver injury in treated mice or in patients during clinical trials. Interleukin-6 (IL-6) has been
reported to protect hepatocyte death, but the role of IL-6 in protecting chronic T cell-induced liver diseases is not clearly
defined due to lack of relevant animal models. We aimed to define the role of IL-6 in CD8+ T cell-mediated liver injury
induced by a CD137 agonistic mAb (clone 2A) in mice.
Methods/Principal Findings: We expressed IL-6 in the liver by hydrodynamic gene delivery in mice treated with 2A or
control mAb and studied how IL-6 treatment affected host immunity and T cell-mediated liver injury. We found that ectopic
IL-6 expression in the liver elevated intrahepatic leukocyte infiltration but prevented CD8+ T cell-mediated liver injury. In IL-
6 treated mice, CD8+ T cells proliferation and IFN-c expression were inhibited in the liver. We discovered that IL-6 increased
accumulation of Gr-1+CD11b+ myeloid derived suppressor cells (MDSCs) in the liver and spleen. These MDSCs had the
ability to inhibit T cells proliferation and activation. Finally, we showed that the MDSCs were sufficient and essential for IL-6-
mediated protection of anti-CD137 mAb-induced liver injury.
Conclusions/Significance: We concluded that IL-6 induced Gr-1+CD11b+ MDSCs in the liver to inhibit T cell-mediated liver
injury. The findings have defined a novel mechanism of IL-6 in protecting liver from CD8+ T cell-mediated injury.
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Introduction
Hepatitis or liver inflammation is a common disease, mainly
caused by hepatitis B or C viruses, alcohol, and various chemical
agents. In addition to direct hepatocyte killing, both innate and
adaptive immune cells contribute to various forms of liver injury,
and CD8+ T cells or cytotoxic T lymphocytes (CTLs) are likely the
main effectors for virus-induced hepatitis[1].
CD137 (4-1BB) is an inducible co-signaling receptor belongs to
the TNF receptor superfamily, which is found on activated T cells,
NK cells, dendritic cells, and macrophages[2]. Engagement of
CD137 provides a costimulatory signal to induce T-cell expansion,
IFN-c production, and prevention of activation-induced death of
effector T cells[3]. In the absence of TCR triggering, CD137
stimulation induces vigorous growth of both CD8+ and CD4+ T
cells with memory phenotype [4]. Treatment with an agonistic
anti-CD137 antibody (clone 2A) in mice can cause CD8+ T cell-
dependent tumor rejection and virus clearance [5,6]. Recently,
using the agonist 2A mAb as a mimicry of CD137L, we set up a
new model for CD8+ T cell-mediated liver injury[7]. A single 2A
treatment triggers hepatic infiltration and activation of CD8+ T
cells, and CD8+ T cell-derived IFN-c plays a central role in the
liver injury[7]. Clinical studies also show that anti-CD137
antibody treatment in some cancer patients leads to liver toxicity,
which leads to suspension of current clinical trials[8,9].
As a pleiotropic cytokine, IL-6 is implicated in both proin-
flammatory and anti-inflammatory responses[10]. In models of
chronic inflammatory diseases, such as arthritis, colitis, or
experimental autoimmune encephalomyelitis, IL-6 plays a proin-
flammatory role [11–14]. Through continuous MCP-1 induction,
it accelerates mononuclear cell accumulation at the site of
inflammation. And it also can promote angioproliferation and
antiapoptotic functions on T cells [10,15]. While in models of
acute inflammation, it exhibits an anti-inflammatory profile[16].
IL-6 also has complicated role in the liver. It is recognized as a
hepatocyte-stimulating factor [17]. During acute and chronic liver
disease, the expression of IL-6 correlates with liver disease
progression [18]. IL-6 could promote liver regeneration [19–21]
and protects hepatocyte death induced by concanavalin A (ConA),
anti-Fas, alcohol, acetaminophen, or carbon tetrachloride medi-
ated hepatic damage through the signal transducer and activator
of transcription 3 (STAT3) pathway after engaging the heterodi-
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protective effect is mediated either by the induction of anti-
apoptotic proteins including Bcl-xL, Bcl-2, and FLIP in the
hepatocytes, or by inducing of soluble factors that regulating
immune function such as serum amyloid A2 and keratinocyte
growth factor[28,29]. In addition, IL-6 may also have direct effects
on immune cells during hepatic injury. A recent study shows that,
in ConA-mediated hepatitis, IL-6 can also inhibit the activity of
NKT cells in a CD4+ T cell and STAT3-dependent manner [30].
However, due to the lack of a model for CD8+ T cell-mediated
chronic hepatitis, whether and how IL-6 plays a role in CTL
mediated hepatitis is still unclear.
Gr-1+CD11b+ myeloid derived suppressor cells (MDSCs) are a
heterogeneous cell population consists of immature myeloid cells
and myeloid progenitor cells that could suppress immune
responses by a variety of mechanisms[31]. Interestingly, IL-6
receptor is expressed on Gr-1+CD11b+ myeloid cells [32]. In a
mouse tumor model, the IL-1R-deficient mouse has a delayed
accumulation of MDSCs, which can be partially restored by IL-
6[32]. Thus IL-6 may induce Gr-1+CD11b+ myeloid cells
expansion in some pathological circumstance.
It is of interest that IL-6 is significantly elevated in patients with
acute and chronic liver diseases [18], but its role in CTL-mediated
hepatitis has not been defined. In this study, we investigated the
role of IL-6 in CD8+ T cell-mediated hepatitis triggered by anti-
CD137 mAb. We showed that IL-6 could prevent CD8+ T cell-
mediated liver injury. Mechanistically, IL-6 induced accumulation
of Gr-1+CD11b+ myeloid cells in the liver, which suppressed T
cell activation to prevent liver injury.
Results
Intrahepatic IL-6 expression in vivo leads to enhanced
liver leukocytes infiltration and splenomegaly but
prevents T cell-mediated liver injury
We have recently established a CD8+ T cell-mediated hepatitis
model induced by a CD137 agonistic mAb (clone 2A) [7]. To
evaluate the potential effect of IL-6 in CD8+ T cell-mediated
chronic hepatitis, we tested the role of IL-6 in the liver
inflammation model induced by 2A[7]. As reported [7], a single
treatment of 2A led to significant infiltration of leukocytes into the
liver in mice (Figure S1A). The CD8+ T cells were
preferentially increased in the liver 10 days after 2A treatment
(Figure S1B–C). We expressed IL-6 protein in mice by
hydrodynamic injection. Two days after injection of IL-6 or
vector control plasmid, the mice were injected with 100 mgo f2 A
or control antibodies and mice were sacrificed at day 12.After
treatment with 2A, we observed liver injury as indicated by the
elevated serum level of alanine aminotransferase (ALT) in mice
(Figure 1A). Interestingly, the 2A treated mice showed no
elevated blood ALT or liver injury if mice were also treated with
IL-6 (Figure 1A). Increase of intrahepatic leukocytes (IHLs)
often correlates with liver inflammation and injury. 2A treatment
increased IHLs by about 2-fold (Figure 1C). However, we found
enlarged livers in the IL-6 treated mice with a 10-fold increase in
IHL infiltration but no obvious liver injury (Figure 1A–D).
In vivo expression of IL-6 also led to obvious splenomegaly
(Figure S2A–B), consistent with the clinical observation that IL-
6 serum concentration correlated with the spleen size as
determined by ultrasound in patient with chronic liver disease
[18]. These results raise intriguing question as to how massive
increase of IHLs by IL-6 led to no sign of liver injury, even
suppressed 2A mediated liver injury.
Proliferation and activation of CD8+ T cells are inhibited
in IL-6 treated mice
CD8+ Tce ll -d e ri v e dI F N - c plays a central rolein 2A-induced liver
injury [7,33]. We investigated whether IL-6 treatment inhibited the
activation of CD8+ T cell in vivo. After IL-6 and 2A treatment, mice
were fed with BrdU for 5 days. The IHLs and splenocytes were
harvested and analyzed for BrdU incorporation at day 10. We found
the IL-6 treated mice showed significant reduction of BrdU+ CD8+
T cells in both liver (Figure 2A) and spleen (Figure S3).B r d U +
CD3+CD82 T cells (CD4+T cells) in the liver showed no significant
difference between the two groups (Figure 2A).I na d d i t i o n ,I F N - c
levels in the liver were also remarkably decreased by about 6 fold
(Figure 2B). When we measured the level of TNF and MCP-1 in
the liver, however, we found no significant difference between IL-6
and the control group (Figure 2B).I ti sp o s s i b l et h a tI L - 6e x p r e s s i o n
or hydro-dynamic injection may stimulate expression of TNF-a and
MCP-1,whichwasnotsufficienttoinduceliverinjury.Therefore,IL-
6 expression in the liver suppressed liver injury, correlated with
reduced proliferation of CD8+ Tc e l l sa n dI F N - c expression.
IL-6 preferentially increases Gr-1+CD11b+ myeloid cells
in the liver and spleen
We speculated that IL-6 may induce cells in the liver with
immune suppressive functions. We next analyzed the intrahepatic
leukocytes by flow cytometry after IL-6 and 2A treatment. As
shown in Figure 3, about 60% of IHLs were indeed found to be
Gr-1+CD11b+ cells in the IL-6 treated mice, while only about 3%
in the control treated group. This was consistent with the H&E
stained liver sections showing the polymorphonuclear feature in
most of the infiltrating leukocytes in the liver of IL-6 treated mice
(Figure 1D). The number of intrahepatic CD4+ T cells
(including FoxP3+CD4+ Treg, data not shown), NK and NKT
cells was not significantly different between the IL-6 and control
groups. However, we found that CD8+ T and B cell numbers
decreased significantly by IL-6 treatment (Figure 3C). Similar
observations were found in the spleen (Figure S4).
Gr-1+CD11b+ myeloid cells induced by IL-6 inhibit T cells
proliferation and activation in vitro
Given that Gr-1+CD11b+ myeloid cells from tumor-bearing
mice could inhibit T cell activation; we investigated if IL-6 induced
Gr-1+CD11b+ myeloid cells can inhibit T cell function. Purified
Gr-1+CD11b+ cells from IL-6-treated mice were added to CFSE-
labeled T cells stimulated with anti-CD3. We found that the Gr-
1+CD11b+ cells efficiently inhibited CD3-mediated T cells
proliferation (Figure 4A–B). The Gr-1+CD11b+ cells also
suppressed IFN-c expression in T cells (Figure 4C). In addition,
IL-6 induced Gr-1+CD11b+ cells could also suppressed ConA
induced T cell activation in vitro (data not shown). Thus IL-6-
induced Gr-1+CD11b+ cells possessed suppressive activity to
inhibit T cells activation and proliferation.
Gr-1+CD11b+ cells induced by IL-6 are sufficient and
essential to protect liver from T cell-mediated injury
We investigated further whether these Gr-1+CD11b+ cells
induced by IL-6 were sufficient and essential to protect 2A-
induced liver injury in vivo. First, we purified CD11b+ Gr-1+ cells
(.95% purity) from the liver of IL-6-treated mice and adoptively
transferred into mice that were pre-treated with anti-CD137 mAb
for 5 days. At day 10, we found significantly lower serum ALT
level (Figure 5A) and less CD8+ T cells infiltration (Figure 5B)
in mice that received Gr-1+CD11b+ cells, indicating that IL-6-
induced Gr-1+CD11b+ cells can protect T cell-mediated liver
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also slightly decreased after transfer (Figure S5A). To test
whether the Gr-1+CD11b+ cells were essential for IL-6 to protect
T cell-mediated liver injury, we treated mice with anti-CD137
mAb and IL-6 as above, followed by anti-Gr-1 antibody (clone
RB6-8C5) injection to deplete Gr-1+ cells. The specific depletion
of Gr-1+ cells were verified by FACS analysis (Figure S5B).
Depletion of Gr-1+ cells in the 2A/IL-6 treated mice led to
disappearance of leukocyte cells infiltration (Figure S5C).
Interestingly, the liver protective effect by IL-6 treatment was
abrogated after depletion of Gr-1+ cells as shown by the significant
increase of serum ALT levels (Figure 5C) and CD8+ T cells were
significantly increased in the liver after Gr-1 depletion
(Figure 5D). Taken together, our data indicated that intrahepatic
expression of IL-6 induced Gr-1+CD11b+ myeloid-derived
suppressor cells to inhibit CD8+ T cell-mediated liver injury.
Discussion
The role of IL-6 in T cell-mediated liver injury is not clearly
defined. We report here that intrahepatic expression of IL-6
induced accumulation of Gr1+CD11b+ myeloid cells in the liver,
which suppressed T cell activation. Furthermore, we showed that
these myeloid cells were sufficient and critical in IL-6-mediated
suppression of T cell-mediated liver injury.
IL-6 has been reported to protect acute liver injury by inhibiting
hepatocyte death [22,24–27]. However, its effect on CD8+ Tc e l l -
mediated liver injury has not been defined. Recently, agonist CD137
mAb treatment has been shown to lead to CD8+ Tc e l l - m e d i a t e d
liver injury in both mouse and human patients. IFN-c induction by
CD8+ T cells in response to anti-CD137 mAb treatment contributed
to liver injury[7]. When IL-6 was expressed in the liver via
hydrodynamic delivery, it effectivelyinhibited the liver injuryinduced
by the CD137 mAb. The Gr1+CD11b+ myeloid cells that were
induced in IL-6-treated mice mediated this protective effect by
inhibiting CD8+ T cells activation and IFN-c induction. In the T cell
suppression assay in vitro, IL6-induced Gr-1+CD11b+ cells inhibited
proliferation of both CD4+ and CD8+ T cells (data not shown).
However, because CD8+ T cells were preferentially increased in the
liver after 2A treatment in vivo (Figure S1B-C), IL-6 significantly
inhibited only proliferation of CD8+ Tc e l l sb u tn o tC D 4 + Tc e l l si n
the liver in vivo (Figure 2A and Figure 3C). Therefore we
Figure 1. Ectopic IL-6 expression in vivo leads to enhanced intrahepatic leukocytes infiltration but protect T cell-mediated liver
injury. C57BL/6 mice were hydrodynamic injected with pcDNA-IL6 plasmid or mock control plasmid at day 0. At day 2, mice were further injected i.p.
with 100 mg 2A antibody or or control antibody (RIg).The mice were sacrificed at day 12, and serum ALT levels (A), liver weight (B) and the number of
intrahepatic leukocytes (C) were measured. (D) At day12, the livers were fixed and stained with H&E. Representative images from 3–4 mice in each
group were shown. Three experiments were performed with similar results. *P,0.05, **P,0.01, ***P,0.001 in comparison with groups as indicated.
doi:10.1371/journal.pone.0017631.g001
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injury by inducing Gr1+CD11b+ myeloid cells which then could
inhibit CD8+ T cells proliferation and IFN-c expression.
Gr1+CD11b+ myeloid cells have been reported in a number of
tumor models where they have been named myeloid-derived
suppressor cells (MDSCs)[31]. The immune regulation functions
of MDSCs in various tumor models have gained special attention
in recent years. Although most of the attention has been focused
on the role of these cells in the field of cancer research,
accumulating evidence has indicated that MDSCs also regulate
immune responses during many other pathological conditions such
infection, autoimmunity and so on[31]. However, there were only
limited data on MDSCs functions in immune-mediated hepatitis.
And at the same time, knowledge about factors that induced
MDSCs production and their homing to peripheral tissues or
lymphoid organs was incomplete. Reports indicated that several
tumor-derived factors induced MDSCs expansion and most of
them triggered signaling pathways in MDSCs that converge on
JAK-STAT3[31]. In this paper, we gave direct evidence that IL-6
can tremendously induce the Gr1+CD11b+ myeloid cells in vivo
(Figure 3) and these cells mediated the liver injury protection
effect of IL-6. Simultaneously, a study also showed that hepatic
gp130 signaling was required for mobilization and accumulation
of MDSCs during polymicrobial sepsis and that hepatic acute-
phase proteins serum amyloid A and Cxcl1/KC cooperatively
play a role in the process [34]. Whether the MDSCs induction
potency of IL-6 in our study was due to its direct effect on myeloid
progenitor cells or its effect on the hepatocyte need further study.
As MDSCs consist of heterogeneous, and not clearly defined,
populations of myeloid lineage cells, it will be of interest to identify
the specific MDSC subset in future experiments.
Elevated IL-6 expression is associated with immune-mediated
liver disease progression. It likely plays a role in protecting liver
injury. However, the prolonged IL-6 expression and MDSCs
accumulation in the liver may have negative effect in promoting
liver disease progression such as liver fibrosis and HCC develop-
ment. In this respect, several studies showed that IL-6 may be a risk
factor for hepatocellular carcinoma development [35–37]. It is also
noteworthy that MDSCs have been shown to accumulate in human
hepatocellular carcinoma [38]. It will be of interest to further test
this hypothesisinrelevant models. Itwillbe ofclinical importanceto
define the role of IL-6 and the ‘‘MDSCs’’ in T cell-mediated liver
injury during viral hepatitis or autoimmune liver diseases. It is
conceivable that IL-6 and the MDSCs mayprovide noveltargetsfor
clinical intervention in treating the immune-mediated diseases.
Materials and Methods
Experimental animal
Female C57BL/6 mice (aged 6–8 wk) were obtained from
Weitonglihua (Beijing, China). The mice were maintained under
specific pathogen-free barrier facility at the Institute of Biophysics,
Chinese Academy of Sciences. All animal studies were approved
by the Animal Welfare and Research Ethics Committee of the
Institute of Biophysics, Chinese Academy of Sciences. Protocol
No. IBP-2008104.
Figure 2. Proliferation and activation of CD8+ T cells were inhibited in vivo in IL-6 treated mice. C57BL/6 mice were treated with IL-6
plasmid and 2A as described in Figure 1 and further fed with drinking water containing 0.8 mg/mL of BrdU from day7 to day12. (A)At day12, the
intrahepatic leukocytes were harvested and BrdU incorporation was analyzed by FACS. Percentage of BrdU+ CD8+ T cells in total CD8+ T cell and total
number of BrdU+ CD8+ T cells in liver were shown. (B) The cytokine levels in the liver homogenate were compared. Representative data from 2
independent experiments with at least 3 mice per group is shown. *P,0.05 in comparison with control groups.
doi:10.1371/journal.pone.0017631.g002
IL-6 Protection of T Cell-Mediated Liver Injury
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17631Flow cytometry, in vivo BrdU labeling, and in vitro
proliferation assay
The antibodies used for FACS staining including anti-mouse
Gr-1-FITC, CD11b-APC, CD4-PE, CD8-FITC, NK1.1-PE,
B220-FITC, CD3-APC, FoxP3-APC were purchased from
eBioscience (San Diego, CA). The in vivo Gr-1+ cells depletion
antibody RB6-8C5 was from BioXCell (West Lebanon, NH). The
anit-CD137 mAb (clone 2A) was described previously [39] and
and rat anti-KLH mAb (clone 6D11) was served as control Rat Ig.
For BrdU labeling experiments, mice were given BrdU (Sigma-
Aldrich, St Louis, MO) daily in the drinking water (0.8 mg/mL),
and the BrdU incorporation was measured by using a BrdU
Figure 3. Gr1+CD11b+ myeloid cells are dramatically increased in the liver. C57BL/6 mice were treated as in Figure. 1. At day 12 the
intrahepatic leukocytes were isolated for FACS analysis. (A) Representative dot plots of Gr-1+CD11b+ cells in the liver. (B) The percentage of Gr-
1+CD11b+ cells in intrahepatic leukocytes in all treated groups. (C) The number of CD4+ T cells, CD8+ T cells, NKT cells, NK cells, B cells, and Gr-
1+CD11b+ cells in the liver of 2A treated mice. Three independent experiments were performed with similar results. **P,0.01, ***P,0.001 in
comparison with control groups or groups as indicated.
doi:10.1371/journal.pone.0017631.g003
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proliferation assay, purified T cells were labeled with 2.5 mM
CFSE (Sigma-Aldrich, St Louis, MO) and then co-cultured with
various amounts of purified CD11b+ cells from the intrahepatic
leukocytes (IHLs) of the IL-6 treated mice in the presence of 6 mg/
ml immobilized anti-CD3 (eBioscience, San Diego, CA) for
60 hours. Two-color flow cytometric analyses were performed
using a FACS Calibur flow cytometer (BD Biosciences,San Jose,
CA) and analyzed using Flowjo software (Tree Star, Ashland, OR).
Plasmid in vivo transfection
The IL-6 cDNA was cloned from LPS stimulated mouse
peritoneal macrophages and inserted into pcDNA-3.1 to construct
the IL-6 expression plasmid, while the mock pcDNA-3.1 was used
as controlplasmid in the study. The plasmids used in thisstudy were
purified byendotoxin-freeplasmidDNApurificationkit(Macherey-
Nagel, Germany). Plasmid DNA was transfected in vivo by using a
hydrodynamic- based gene transfer technique. Briefly, 10 mg/
mouse DNA was diluted in 2.0 ml of PBS (,0.1 ml/g body weight)
and injected into the tail vein using a 27-gauge needle and syringe
withinatime periodof5 to8seconds.Theexpression ofIL-6invivo
wasconfirmedbydetectingthe IL-6inthe serumwith a commercial
ELISA kit from eBioscience (San Diego, CA) 24 hours after
hydrodynamic injection (data not shown).
Cell preparation
Mouse intrahepatic leukocytes (IHLs) were isolated as described
previously [40]. For CD11b+ cell isolation, the CD11b+ IHLs from
IL-6 treated mice were further isolated by positive selection (Miltenyi
Biotec, Auburn, CA). About 95% of the purified CD11b+ cells were
CD11b+ Gr-1+ cells (Data not shown). To purify T cells, splenocytes
from naı ¨ve C57BL/6 mice were negative selected by exclusion of
NK1.1+,G r - 1 +, CD11b+,B 2 2 0 + cells. The purity of CD3+ T
lymphocytes after selection was over 90% as confirmed by FACS.
Cytokine and Serum ALT Analysis
The cytokine levels in tissue homogenates of mice was analyzed
using CBA inflammation kit (BD Pharmingen, San Diego, CA) on
a FACS Calibur Cytometer (BD Bioscience, San Jose, CA). The
serum ALT was measured by using a commercial kit (Biosino
Company, Beijing, China) on Nipro Miracle ACE 919 automated
biochemical analyzer (Nissho Electronics, Japan).
Hematoxylin-eosin and immunofluorescence staining of
liver sections
The livers were fixed with 4% Paraform aldehyde (PFA),
embedded, sliced and further stained with hematoxylin-eosin for
pathological analysis. For immunofluorescence staining, cryosec-
tions of frozen livers were performed and slides were fixed with
acetone. CD8 immunofluorescence staining was performed by
using rat anti-mouse CD8 antibody (Biolegend, San Diego, CA).
As a second antibody, Alexa Fluor 555 goat anti-rat IgG
(Invitrogen, Carlsbad, CA) was used. DAPI (BD Pharmingen,San
Diego, CA) counterstaining was used to detect nuclei.
Statistics
Statistical analyses were performed with the Graphpad prism 4
(Graphpad, San Diego,CA). Error bars represent as s.e.m. P value
Figure 4. Gr-1+CD11b+ myeloid cells inhibit T cells proliferation and activation in vitro. Purified 3610
5CFSE labeled T cells were cultured
with 6 mg/mL anti-CD3, in the presence of different ratio of purified CD11b+Gr-1+ cells. CD11b+ cells purification procedure was described in
Materials and Methods. 60 hour later, the cells were harvested and analyzed by FACS. (A) Representative histograms showing the proliferation of T
cells with different ratios of purified CD11b+Gr-1+ cells. (B–C) The relative proliferation and IFN-c production were measured by CFSE dilution or
ELISA, respectively. Proliferation of T cells without CD11b+ cells was set as 100%. The experiment was performed in triplicates. *P,0.05, **P,0.01,
***P,0.001 in comparison with T cells alone.
doi:10.1371/journal.pone.0017631.g004
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0.001 was shown as ** or ***, respectively.
Supporting Information
Figure S1 2A treatment leads to intrahepatic leukocytes
infiltration. C57BL/6 mice were injected i.p. with 100 mg2 A
antibody or or control antibody (RIg). At day 10, the intrahepatic
leukocytes (IHLs) were isolated for FACS staining. (A) The total
number of IHLs. (B) The frequency of each subset in IHLs, and
(C) The number of each subset in IHLs were showed.
(TIF)
Figure S2 Ectopic IL-6 expression in vivo leads to
splenomegaly. C57BL/6 mice were treated as in Figure 1. At
day 12, the mice were sacrificed and typical spleen morphology
was showed in (A). (B) Indicated spleen cell numbers in each
group. Three experiments with similar results were performed.
**P,0.01, ***P,0.001 in comparison with groups as indicated.
(TIF)
Figure S3 Proliferation of CD8+ T cells is inhibited in
the spleen in IL-6 treated mice. C57BL/6 mice were treated
as in Figure 2. At day12, the spleen cells were harvest and BrdU
incorporation was analyzed by FACS. Percentage of BrdU+ CD8+
T cells in total CD8+ T cell in spleen and the number of BrdU+
CD8+ T cells were showed. Representative data from 2
independent experiments with at least 3 mice per group is shown.
*P,0.05, **P,0.01 in comparison with control groups.
(TIF)
Figure S4 Gr1+CD11b+ myeloid cells are dramatically
increased in the spleen. C57BL/6 mice were treated as in
Figure 3. At day 12 the spleen cells were isolated for FACS
analysis. (A) Representative staining of Gr-1+CD11b+ cells in the
spleen. (B) The percentage of Gr-1+CD11b+ cells in spleen cells.
(C) The number of CD4+ T cells, CD8+ T cells, NKT cells, NK
cells, B cells, and Gr-1+CD11b+ cells in the spleen of 2A treated
mice. Graphs represent the mean (SD) of 3–5 mice each group.
Three independent experiments were performed with similar
results. *P,0.05, **P,0.01, ***P,0.001 in comparison with
control groups or groups as indicated.
(TIF)
Figure S5 Adoptive transfer and depletion of MDSCs in
vivo. (A) C57BL/6 mice were treated as in Figure 5A. At day 10
Figure 5. Gr-1+CD11b+ myeloid cells mediate the liver protective effect of IL-6. (A) C57BL/6 mice were i.p. injected with 100 mg 2A at day 0,
and then adoptively transferred with 1610
7 CD11b+ intrahepatic leukocytes from IL-6 treated mice or PBS as control at day 5. ALT levels in serum
were detected at day 10. CD11b+ cells purification procedure was described in Materials and Methods. Representative data from 2 independent
experiments with at least 3 mice per group was shown. (B) Detection of CD8+ T cells (red color) in liver sections. Mice were treated as in (A). DAPI
counterstaining was used to detect nuclei. (C) C57BL/6 mice were hydrodynamic injected with pcDNA-IL6 plasmid or mock plasmid at day 0. At day 2,
they were i.p. injected with 2A antibody. 300 mg of anti-Gr-1 antibody or control Rat IgG were given at day 2, 4, 6, 9, and ALT levels in serum were
detected at day 12. (D) Detection of CD8 T+ cells (red color) in liver sections. Mice were treated as in (C). DAPI counterstaining was used to detect
nuclei. Representative data from 2 independent experiments with at least 3 mice per group is shown. *P,0.05, **P,0.01 in comparison with control
groups or groups as indicated.
doi:10.1371/journal.pone.0017631.g005
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treated as in Figure 5C. At day 10 the peripheral blood leukocytes
of the mice were collected and stained for Gr-1+ CD11b+ cells. (C)
Mice were treated as in Figure 5C. At day12, the livers were fixed
and stained with H&E.
(TIF)
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